Assessment of the analytical performance of point-of-care faecal immunochemical tests for haemoglobin.


Journal

Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055

Informations de publication

Date de publication:
May 2021
Historique:
pubmed: 24 12 2020
medline: 18 5 2021
entrez: 23 12 2020
Statut: ppublish

Résumé

The faecal immunochemical test (FIT) detects the presence of haemoglobin (Hb) in faeces. It is used as a screening tool for colorectal cancer (CRC) and increasingly to triage patients presenting with symptoms of CRC. A number of quantitative point-of-care (POC) FIT systems marketed for professional use and intended for use in a clinical setting are available. Here we reviewed the POC FIT systems available; three (Eurolyser Cube, OC-Sensor iO and QuikRead go) were evaluated to assess their performance against manufacturers' claims and suitability for use in a clinical setting. The analytical evaluation of the POC FIT systems was undertaken using Hb lysates, patient samples and an external quality assessment sample. The evaluation focused on linearity, recovery, imprecision, prozone effect, Hb variant detection and suitability for use in a clinical setting. All three POC FIT systems performed to their manufacturer's claims and demonstrated good analytical performance with acceptable linearity, recovery, within- and between-run imprecision. The QuikRead go and OC-Sensor iO were able to accurately detect samples with results above their measuring range. However, because of a prozone effect the Eurolyser Cube gave falsely low results when using high concentrations of Hb. The QuikRead go performed best in the usability assessment due to portability and timeliness of result. Each system performed according to their manufacturers' claims. The QuikRead go and OC-Sensor iO are suitable for use. The Eurolyser Cube is not recommended because of the risk of falsely low results.

Sections du résumé

BACKGROUND BACKGROUND
The faecal immunochemical test (FIT) detects the presence of haemoglobin (Hb) in faeces. It is used as a screening tool for colorectal cancer (CRC) and increasingly to triage patients presenting with symptoms of CRC. A number of quantitative point-of-care (POC) FIT systems marketed for professional use and intended for use in a clinical setting are available. Here we reviewed the POC FIT systems available; three (Eurolyser Cube, OC-Sensor iO and QuikRead go) were evaluated to assess their performance against manufacturers' claims and suitability for use in a clinical setting.
METHODS METHODS
The analytical evaluation of the POC FIT systems was undertaken using Hb lysates, patient samples and an external quality assessment sample. The evaluation focused on linearity, recovery, imprecision, prozone effect, Hb variant detection and suitability for use in a clinical setting.
RESULTS RESULTS
All three POC FIT systems performed to their manufacturer's claims and demonstrated good analytical performance with acceptable linearity, recovery, within- and between-run imprecision. The QuikRead go and OC-Sensor iO were able to accurately detect samples with results above their measuring range. However, because of a prozone effect the Eurolyser Cube gave falsely low results when using high concentrations of Hb. The QuikRead go performed best in the usability assessment due to portability and timeliness of result.
CONCLUSION CONCLUSIONS
Each system performed according to their manufacturers' claims. The QuikRead go and OC-Sensor iO are suitable for use. The Eurolyser Cube is not recommended because of the risk of falsely low results.

Identifiants

pubmed: 33353372
doi: 10.1177/0004563220986595
doi:

Substances chimiques

Hemoglobins 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-189

Auteurs

Shane O'Driscoll (S)

Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Guildford, UK.
Berkshire and Surrey Pathology Services, Guildford, UK.
Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

Magdalen Carroll (M)

Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Guildford, UK.
Berkshire and Surrey Pathology Services, Guildford, UK.
Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

William Maclean (W)

Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

Carolyn Piggott (C)

Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Guildford, UK.
Berkshire and Surrey Pathology Services, Guildford, UK.
Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

Iain Jourdan (I)

Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

Sally C Benton (SC)

Bowel Cancer Screening Programme, Southern Hub, Royal Surrey County Hospital, Guildford, UK.
Berkshire and Surrey Pathology Services, Guildford, UK.
Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH